Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus letrozole biomarker study in first-line hormone receptor-positive advanced breast cancer
2013-004139-62Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Correlation of mTOR pathway biomarkers with 6-month progression-free rate. Started Nov 2013; status: terminated.
02
Drugs
everolimusletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004139-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004139-62.